Frontlight ResearchEarly access
CompletedPhase 2
A feasibility study of SGM-101, a fluorochrome-labeled anti-carcinoembryonic antigen monoclonal antibody for the intraoperative detection of colorectal brain metastases.
Key facts
- Who runs it
- Academisch Ziekenhuis Leiden
- Where
- Netherlands2 sites in 1 countryChoose a country to see its sites
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 10 people enrolled
- Started
- 4 Dec 2023
- Ended
- 11 Jun 2025
- Type of study
- Interventional
- Record updated
- 16 October 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Signed informed consent prior to any study-mandated procedure
- Patients aged over 18 years old
- All women of child bearing potential and all males must practice effective contraception during the study and be willing and able to continue contraception for at least 30 days after their last dose of study treatment
- Has the ability to communicate well with the Investigator in the Dutch language and willing to comply with the study restrictions
- Diagnosed with brain metastasis of colorectal origin and scheduled for a resection
Who cannot take part
- History of any anaphylactic reaction; 7. Previous use of SGM-101
- Previous use of SGM-101
- Patients pregnant or breastfeeding (pregnancy should be ruled out by a pregnancy test within two weeks prior to administration of the conjugate)
- Other malignancies either currently active or diagnosed in the last 5 years, except adequately treated in situ carcinoma of the cervix and basal or squamous cell skin carcinoma
- Any condition that the investigator considers to be potentially jeopardizing the patient’s well-being or the study objectives (following a detailed medical history, physical examination, vital signs (systolic and diastolic blood pressure, pulse rate, body temperature) and 12-lead electrocardiogram (ECG)). Minor deviations from the normal range may be accepted, if judged by the Investigator to have no clinical relevance
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To assess the performance of SGM-101 in the intraoperative detection of brain metastases of colorectal origin.
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- SGM-CBM: A feasibility study of SGM-101, a fluorochrome-labeled anti-carcinoembryonic antigen monoclonal antibody for the intraoperative detection of colorectal brain metastases.
- Record updated
- 16 October 2024